Benzinga's Top #PreMarket Gainers

Intercept Pharmaceuticals

shares jumped 119.43% to $159.00 in pre-market trading after the company reported that the FLINT trial of obeticholic acid has been stopped early and the NASH primary endpoint has been met. Sangamo Biosciences

shares gained 13.64% to $15.50 in the pre-market after the company and Biogen Idec

announced the global collaboration to develop treatments for hemoglobinopathies. Sequenom

surged 10.16% to $2.71 in the pre-market session after the company announced the issuance of European patent for novel methods of detecting fetal aneuploidy. Macy's

soared 7.06% to $55.50 in the pre-market trading after the company announced its plans to lower 2,500 jobs and shut five Macy's stores. It also reported a 3.6% rise in its comparable sales in November and December. The retailer also issued upbeat outlook for 2014. BMO Capital upgraded the stock from Market Perform to Outperform and lifted the target price from $53 to $70.